Journal article
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
Annals of clinical and translational neurology, Vol.7(4), pp.449-461
04/2020
DOI: 10.1002/acn3.51022
PMCID: PMC7187707
PMID: 32285645
Abstract
To determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from disease onset.
Prospectively collected, longitudinal (untreated, disease onset to year 5), observational data from Parkinson's Progression Markers Initiative annual visits was used to evaluate prevalence, correlates, and treatment of 10 neuropsychiatric symptoms and cognitive impairment in Parkinson disease participants and matched healthy controls.
Of 423 Parkinson disease participants evaluated at baseline, 315 (74.5%) were assessed at year 5. Eight neuropsychiatric symptoms studied increased in absolute prevalence by 6.2-20.9% at year 5 relative to baseline, and cognitive impairment increased by 2.7-6.2%. In comparison, the frequency of neuropsychiatric symptoms in healthy controls remained stable or declined over time. Antidepressant and anxiolytic/hypnotic use in Parkinson disease were common at baseline and increased over time (18% to 27% for the former; 13% to 24% for the latter); antipsychotic and cognitive-enhancing medication use was uncommon throughout (2% and 5% of patients at year 5); and potentially harmful anticholinergic medication use was common and increased over time. At year 5 the cross-sectional prevalence for having three or more neuropsychiatric disorders/cognitive impairment was 56% for Parkinson disease participants versus 13% for healthy controls, and by then seven of the examined disorders had either occurred or been treated at some time point in the majority of Parkinson disease patients. Principal component analysis suggested an affective disorder subtype only.
Neuropsychiatric features in Parkinson disease are common from the onset, increase over time, are frequently comorbid, and fluctuate in severity.
Details
- Title: Subtitle
- Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
- Creators
- Daniel Weintraub - Parkinson's Disease Research, Education and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PennsylvaniaChelsea Caspell-Garcia - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IowaTanya Simuni - Feinberg School of Medicine, Northwestern University, Chicago, IllinoisHyunkeun R Cho - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IowaChristopher S Coffey - Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IowaDag Aarsland - Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, EnglandRoy N Alcalay - Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, New YorkMatthew J Barrett - Department of Neurology, Virginia Commonwealth University, Richmond, VirginiaLana M Chahine - Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PennsylvaniaJamie Eberling - Michael J. Fox Foundation for Parkinson's Research, New York, New YorkAlberto J Espay - Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, OhioJamie Hamilton - Michael J. Fox Foundation for Parkinson's Research, New York, New YorkKeith A Hawkins - Department of Psychiatry, Yale School of Medicine, New Haven, ConnecticutJames Leverenz - Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, OhioIrene Litvan - UCSD Movement Disorder Center, Department of Neurosciences, University of California San Diego, San Diego, CaliforniaIrene Richard - Departments of Neurology and Psychiatry, School of Medicine and Dentistry, University of Rochester, Rochester, New YorkLiana S Rosenthal - Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MarylandAndrew Siderowf - Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaMichele York - Departments of Neurology and Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TexasParkinson’s Progression Markers Initiative
- Resource Type
- Journal article
- Publication Details
- Annals of clinical and translational neurology, Vol.7(4), pp.449-461
- DOI
- 10.1002/acn3.51022
- PMID
- 32285645
- PMCID
- PMC7187707
- NLM abbreviation
- Ann Clin Transl Neurol
- ISSN
- 2328-9503
- eISSN
- 2328-9503
- Grant note
- DOI: 10.13039/100000864, name: Michael J. Fox Foundation for Parkinson's Research
- Language
- English
- Date published
- 04/2020
- Academic Unit
- Biostatistics
- Record Identifier
- 9984214694002771
Metrics
23 Record Views